Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 4
2013 1
2014 1
2015 1
2016 1
2017 1
2018 1
2020 1
2021 4
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
The potential of PARP as a therapeutic target across pediatric solid malignancies.
Keller KM, Koetsier J, Schild L, Amo-Addae V, Eising S, van den Handel K, Ober K, Koopmans B, Essing A, van den Boogaard ML, Langenberg KPS, Jäger N, Kool M, Pfister S, Dolman MEM, Molenaar JJ, van Hooff SR. Keller KM, et al. Among authors: schild l. BMC Cancer. 2023 Apr 5;23(1):310. doi: 10.1186/s12885-022-10319-7. BMC Cancer. 2023. PMID: 37020198 Free PMC article.
MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma.
Eleveld TF, Vernooij L, Schild L, Koopmans B, Alles LK, Ebus ME, Dandis R, van Tinteren H, Caron HN, Koster J, van Noesel MM, Tytgat GAM, Eising S, Versteeg R, Dolman MEM, Molenaar JJ. Eleveld TF, et al. Among authors: schild l. Front Oncol. 2023 Feb 21;13:1130034. doi: 10.3389/fonc.2023.1130034. eCollection 2023. Front Oncol. 2023. PMID: 36895472 Free PMC article.
Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program 'iTHER'.
Langenberg KPS, Meister MT, Bakhuizen JJ, Boer JM, van Eijkelenburg NKA, Hulleman E, Ilan U, Looze EJ, Dierselhuis MP, van der Lugt J, Breunis W, Schild LG, Ober K, van Hooff SR, Scheijde-Vermeulen MA, Hiemcke-Jiwa LS, Flucke UE, Kranendonk MEG, Wesseling P, Sonneveld E, Punt S, Boltjes A, van Dijk F, Verwiel ETP, Volckmann R, Hehir-Kwa JY, Kester LA, Koudijs MMJ, Waanders E, Holstege FCP, Vormoor HJ, Hoving EW, van Noesel MM, Pieters R, Kool M, Stumpf M, Blattner-Johnson M, Balasubramanian GP, Van Tilburg CM, Jones BC, Jones DTW, Witt O, Pfister SM, Jongmans MCJ, Kuiper RP, de Krijger RR, Wijnen MHW, den Boer ML, Zwaan CM, Kemmeren P, Koster J, Tops BBJ, Goemans BF, Molenaar JJ. Langenberg KPS, et al. Among authors: schild lg. Eur J Cancer. 2022 Nov;175:311-325. doi: 10.1016/j.ejca.2022.09.001. Epub 2022 Sep 29. Eur J Cancer. 2022. PMID: 36182817 Free PMC article.
Two opposing gene expression patterns within ATRX aberrant neuroblastoma.
van Gerven MR, Schild L, van Arkel J, Koopmans B, Broeils LA, Meijs LAM, van Oosterhout R, van Noesel MM, Koster J, van Hooff SR, Molenaar JJ, van den Boogaard ML. van Gerven MR, et al. Among authors: schild l. PLoS One. 2023 Aug 4;18(8):e0289084. doi: 10.1371/journal.pone.0289084. eCollection 2023. PLoS One. 2023. PMID: 37540673 Free PMC article.
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.
Eleveld TF, Oldridge DA, Bernard V, Koster J, Colmet Daage L, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, Lapouble E, Combaret V, Legoix-Né P, Michon J, Pugh TJ, Hart LS, Rader J, Attiyeh EF, Wei JS, Zhang S, Naranjo A, Gastier-Foster JM, Hogarty MD, Asgharzadeh S, Smith MA, Guidry Auvil JM, Watkins TB, Zwijnenburg DA, Ebus ME, van Sluis P, Hakkert A, van Wezel E, van der Schoot CE, Westerhout EM, Schulte JH, Tytgat GA, Dolman ME, Janoueix-Lerosey I, Gerhard DS, Caron HN, Delattre O, Khan J, Versteeg R, Schleiermacher G, Molenaar JJ, Maris JM. Eleveld TF, et al. Among authors: schild l. Nat Genet. 2015 Aug;47(8):864-71. doi: 10.1038/ng.3333. Epub 2015 Jun 29. Nat Genet. 2015. PMID: 26121087 Free PMC article.
Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma.
Keller KM, Eleveld TF, Schild L, van den Handel K, van den Boogaard M, Amo-Addae V, Eising S, Ober K, Koopmans B, Looijenga L, Tytgat GAM, Ylstra B, Molenaar JJ, Dolman MEM, van Hooff SR. Keller KM, et al. Among authors: schild l. Front Oncol. 2022 Sep 27;12:929123. doi: 10.3389/fonc.2022.929123. eCollection 2022. Front Oncol. 2022. PMID: 36237330 Free PMC article.
High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells.
Vernooij L, Bate-Eya LT, Alles LK, Lee JY, Koopmans B, Jonus HC, Schubert NA, Schild L, Lelieveld D, Egan DA, Kerstjens M, Stam RW, Koster J, Goldsmith KC, Molenaar JJ, Dolman MEM. Vernooij L, et al. Among authors: schild l. Mol Cancer Ther. 2021 Jun;20(6):1161-1172. doi: 10.1158/1535-7163.MCT-20-0666. Epub 2021 Apr 13. Mol Cancer Ther. 2021. PMID: 33850004 Free PMC article.
Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastoma.
van den Boogaard ML, Oka R, Hakkert A, Schild L, Ebus ME, van Gerven MR, Zwijnenburg DA, Molenaar P, Hoyng LL, Dolman MEM, Essing AHW, Koopmans B, Helleday T, Drost J, van Boxtel R, Versteeg R, Koster J, Molenaar JJ. van den Boogaard ML, et al. Among authors: schild l. Proc Natl Acad Sci U S A. 2021 Sep 7;118(36):e2007898118. doi: 10.1073/pnas.2007898118. Proc Natl Acad Sci U S A. 2021. PMID: 34479993 Free PMC article.
Neuroblastoma and DIPG Organoid Coculture System for Personalized Assessment of Novel Anticancer Immunotherapies.
M Kholosy W, Derieppe M, van den Ham F, Ober K, Su Y, Custers L, Schild L, M J van Zogchel L, M Wellens L, R Ariese H, Szanto CL, Wienke J, Dierselhuis MP, van Vuurden D, Dolman EM, Molenaar JJ. M Kholosy W, et al. Among authors: schild l. J Pers Med. 2021 Aug 30;11(9):869. doi: 10.3390/jpm11090869. J Pers Med. 2021. PMID: 34575646 Free PMC article.
19 results